Titre:
  • Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial.
Auteur:Pestalozzi, B C; Francis, P; Quinaux, E; Dolci, Stella; Azambuja, Evandro; Gelber, R D; Viale, G; Balil, A; Andersson, M; Nordenskjöld, B; Gnant, Michael; Gutierrez, J; Láng, I; Crown, J P A; Piccart-Gebhart, Martine; BIG 02-98 Collaborative Group,
Informations sur la publication:Annals of oncology, 19, 11, page (1837-1841)
Statut de publication:Publié, 2008-11
Sujet CREF:Sciences bio-médicales et agricoles
Mots-clés:Adjuvant chemotherapy
Breast cancer
Central nervous system
Meningeal carcinomatosis
Taxane
Trastuzumab
MeSH keywords:Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- cerebrospinal fluid
Breast Neoplasms -- drug therapy
Breast Neoplasms -- pathology
Central Nervous System Neoplasms -- cerebrospinal fluid
Central Nervous System Neoplasms -- secondary
Chemotherapy, Adjuvant
Cyclophosphamide -- administration & dosage
Doxorubicin -- administration & dosage
Female
Fluorouracil -- administration & dosage
Humans
Methotrexate -- administration & dosage
Middle Aged
Neoplasm Metastasis
Taxoids -- administration & dosage
Taxoids -- adverse effects
Treatment Failure
Note générale:Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langue:Anglais
Identificateurs:urn:issn:0923-7534
info:doi/10.1093/annonc/mdn385
info:pii/mdn385
info:scp/54949136570
info:pmid/18562328
PMC2733076